When exploring the pathophysiological mechanisms of IBD and IBS, three common factors emerge:
1. Increased intestinal permeability.
3. Dysbiosis of the microbiome
Current treatment options for IBS and IBD are limited due to the complex pathophysiology of these conditions and as such, there is a severe unmet clinical need for products that can treat each of these primary underlying factors, and induce and maintain remission in patients.
Anatara has been actively working on the development of the GaRP product and has completed the dose selection of each formulation component. The Company has recently generated excellent in vitro and in vivo preclinical data to support the effectiveness of GaRP in:
• Removing bacteria with pro-inflammatory properties;
• Reducing inflammation by reducing the release of pro-inflammatory cytokines;
• Regenerating the integrity of the gastrointestinal tract; and
• Stimulating mucosal healing.
The design of GaRP has been enabled by leveraging published research in conjunction with the extensive body of knowledge generated in-house at Anatara. Bromelain is one of the main components of GaRP and therefore forms the basis of its acceptability as an effective dietary supplement.
With a triple-targeted therapeutic approach (anti-adhesion, anti-inflammatory and mucosal regeneration) and a dual targeted formulation, Anatara believes it will deliver components to where they can be most effective and provide broad symptomatic relief to IBS and IBD patients.